IDEAYA Biosciences, Inc. Common Stock (IDYA) Stock Price

IDYAStock

$42.48+59.39%52W

Market Cap$4.10B

P/E—

PEG Ratio—

Div yield—

Beta-0.06

IDYA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)18.25%

Price vs S&P 500 (4W)7.68%

VGM Score69.20

Book Value / Share (Quarterly)$12.44

P/TBV (Annual)5.83x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)62.54%

Cash Flow / Share (Quarterly)$-1.18

Price vs S&P 500 (YTD)3.86%

Net Profit Margin (TTM)-74.75%

EPS (TTM)$-1.94

10-Day Avg Trading Volume0.72M

EPS Excl Extra (TTM)$-1.94

Revenue Growth (5Y)62.10%

EPS (Annual)$-1.28

ROI (Annual)-11.11%

Net Profit Margin (5Y Avg)-949.88%

Cash / Share (Quarterly)$8.60

Revenue Growth QoQ (YoY)55.37%

ROA (Last FY)-10.25%

Revenue Growth TTM (YoY)3118.14%

EBITD / Share (TTM)$-2.39

ROE (5Y Avg)-17.70%

Operating Margin (TTM)-92.66%

Cash Flow / Share (Annual)$-0.84

P/B Ratio2.96x

P/B Ratio (Quarterly)2.96x

Net Income / Employee (Annual)$-784,100

EV / Revenue (TTM)14.00x

ROA (TTM)-15.11%

EPS Incl Extra (Annual)$-1.28

Current Ratio (Annual)11.34x

Quick Ratio (Quarterly)10.21x

3-Month Avg Trading Volume1.03M

52-Week Price Return59.39%

Revenue / Employee (TTM)$1,614,700

Tangible BV / Share (Quarterly)$8.67

P/S Ratio (Annual)16.24x

Asset Turnover (Annual)0.20x

52-Week High$40.58

Operating Margin (5Y Avg)-1124.28%

EPS Excl Extra (Annual)$-1.28

CapEx CAGR (5Y)37.04%

Tangible BV CAGR (5Y)102.18%

26-Week Price Return29.50%

Quick Ratio (Annual)10.97x

13-Week Price Return35.55%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)10.45x

Enterprise Value$3.28B

Revenue / Share Growth (5Y)25.61%

Asset Turnover (TTM)0.20x

Book Value / Share Growth (5Y)11.63%

Revenue / Employee (Annual)$1,508,300

Pretax Margin (Annual)-51.99%

Cash / Share (Annual)$7.28

3-Month Return Std Dev50.31%

Net Income / Employee (TTM)$-1,207,000

ROE (Last FY)-11.11%

EPS Basic Excl Extra (Annual)$-1.28

Receivables Turnover (TTM)73.20x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.94

Receivables Turnover (Annual)73.20x

ROI (TTM)-16.47%

P/S Ratio (TTM)15.17x

Pretax Margin (5Y Avg)-949.88%

Revenue / Share (Annual)$2.47

Tangible BV / Share (Annual)$7.25

Price vs S&P 500 (52W)41.08%

Year-to-Date Return15.82%

5-Day Price Return5.56%

EPS Normalized (Annual)$-1.28

ROA (5Y Avg)-16.05%

Net Profit Margin (Annual)-51.99%

Month-to-Date Return12.79%

Cash Flow / Share (TTM)$-1.89

EBITD / Share (Annual)$-1.77

Operating Margin (Annual)-72.84%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-17.70%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.94

P/TBV (Quarterly)4.01x

P/B Ratio (Annual)2.96x

Pretax Margin (TTM)-74.75%

Book Value / Share (Annual)$11.65

Price vs S&P 500 (13W)32.75%

Beta-0.06x

P/FCF (Annual)64.60x

Revenue / Share (TTM)$2.54

ROE (TTM)-16.47%

52-Week Low$23.23

vGradeC

gGradeA

mGradeB

vgmGradeB

IDYA Earnings Surprise History

Q2 25-0.88est. -0.79

Q3 251.33est. -0.55

Q4 25-0.94est. -0.95

Q1 26-1.11est. -0.98

Q2 26-1.22est. -1.05

IDYA Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.24

4.17

4.23

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
IDYAIDEAYA Biosciences, Inc. Common Stock	C	A	B	$42.48
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About IDEAYA Biosciences, Inc. Common Stock

IDEAYA Biosciences is an oncology-focused precision medicine company developing targeted cancer therapies selected using molecular diagnostics and biomarker validation. It combines small molecule drug discovery with translational research to identify patient populations most likely to benefit from its treatments. The company has six clinical-stage candidates and multiple earlier-stage preclinical programs in development.